Achieving Remission in Chronic Rhinosinusitis With Nasal Polyps Depends on Practical Utilization of Current Criteria and Does not Reflect Therapy Response : Results From a Multi‐National Cohort
Open Access
- 4 October 2026
- journal article
- letter
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70211
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Clinical Remission in Chronic Rhinosinusitis With Nasal Polyps: a Delphi Consensus from the Rhinosinusitis Italian Network (RINET)The Journal of Allergy and Clinical Immunology: In Practice, 2026
- Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering DosageAllergy, 2025
- Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory DiseaseAllergy, 2025
- Almost Half of the Dupilumab‐Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One YearAllergy, 2025
- EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNPRhinology journal, 2024
- EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023Rhinology journal, 2023
- Clinical Usefulness of Self-Rated Olfactory Performance—A Data Science-Based Assessment of 6000 PatientsChemical Senses, 2019